Zvi Fuchs - Atrys Health Founder VP
| ATRY Stock | EUR 3.23 0.04 1.22% |
Insider
Zvi Fuchs is Founder VP of Atrys Health SL
| Phone | 34 91 781 94 65 |
| Web | https://www.atryshealth.com |
Atrys Health Management Efficiency
Atrys Health's management efficiency ratios could be used to measure how well Atrys Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ignacio Toledano | Laboratorios Farmaceuticos ROVI | N/A | |
| Sonia Bezon | Oryzon Genomics SA | N/A | |
| Fernando Garijo | Laboratorios Farmaceuticos ROVI | N/A | |
| Francisco Garca | Laboratorios Farmaceuticos ROVI | N/A | |
| Emili Cortada | Oryzon Genomics SA | N/A | |
| Beatriz Alcalde | Laboratorios Farmaceuticos ROVI | N/A | |
| Michael Ropacki | Oryzon Genomics SA | N/A | |
| Neus Bernado | Oryzon Genomics SA | N/A | |
| M Perez | Laboratorios Farmaceuticos ROVI | N/A | |
| Xavier Ribera | Oryzon Genomics SA | N/A | |
| Mercedes Sanchez | Laboratorios Farmaceuticos ROVI | N/A | |
| Rosario Prez | Laboratorios Farmaceuticos ROVI | N/A | |
| Saikat Nandi | Oryzon Genomics SA | N/A | |
| Ana Limon | Oryzon Genomics SA | N/A | |
| Marcos Pinto | Laboratorios Farmaceuticos ROVI | N/A | |
| Jordi Pey | Oryzon Genomics SA | N/A | |
| Fatima Garcia | Laboratorios Farmaceuticos ROVI | N/A | |
| Mercedes Snchez | Laboratorios Farmaceuticos ROVI | N/A | |
Management Performance
| Return On Equity | -0.0723 | |||
| Return On Asset | 0.0022 |
Atrys Health SL Leadership Team
Elected by the shareholders, the Atrys Health's board of directors comprises two types of representatives: Atrys Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atrys. The board's role is to monitor Atrys Health's management team and ensure that shareholders' interests are well served. Atrys Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atrys Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Santiago Sanahuja, Executive Chairman of the Board | ||
| Helena VidalFolch, Head Communication | ||
| Gabriela Camunas, G Counsel | ||
| Carlos CordonCardo, Scientific Vice President | ||
| Anna Valero, Diagnostics Director | ||
| Encarna Vega, Adm Director | ||
| Maria Marin, Head Relations | ||
| Isabel Fernandez, Chief Executive Officer | ||
| Carlo Greco, Vice President of Medical Radiotherapy | ||
| Victor Rumayor, R&D Director | ||
| Jose Ginesta, Chief Financial Officer | ||
| Zvi Fuchs, Founder VP | ||
| Eduardo Dussel, Director of Teleradiology | ||
| Carlos Girn, Chief Officer |
Atrys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atrys Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0723 | |||
| Return On Asset | 0.0022 | |||
| Profit Margin | (0.13) % | |||
| Operating Margin | 0.01 % | |||
| Current Valuation | 647.57 M | |||
| Shares Outstanding | 75.89 M | |||
| Shares Owned By Insiders | 78.47 % | |||
| Shares Owned By Institutions | 11.00 % | |||
| Price To Book | 1.28 X | |||
| Price To Sales | 2.47 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Atrys Stock
Atrys Health financial ratios help investors to determine whether Atrys Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Atrys with respect to the benefits of owning Atrys Health security.